The Division of Monoclonal Antibodies




        Kathleen A. Clouse, Ph.D., Director
             CTGTAC - July 26, 2007
Mission of the DMA

… to ensure that safe, efficacious, and high quality
   monoclonal antibody and related products are
 ...
Clinical Success of Monoclonal Antibodies


  “Monoclonal antibodies now comprise the majority of
  recombinant proteins c...
The Division of Monoclonal Antibodies
                                        Kathleen Clouse, PhD.
                      ...
Dr. David Frucht
• Established an independent research program to characterize
  the activity of anthrax lethal toxin in v...
Dr. David Frucht
• Board certified in Internal Medicine & Infectious Diseases
• Performs weekly clinical rounds at NIH
• S...
David Frucht, M.D.
            Research Program Objectives

• Identify biological markers for the activity of anthrax leth...
David Frucht, M.D.
           Research Program Milestones
• Anthrax LT activates murine macrophages, leading to release of...
Upcoming SlideShare
Loading in...5
×

The Division of Monoclonal Antibodies

476

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
476
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
20
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The Division of Monoclonal Antibodies

  1. 1. The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007
  2. 2. Mission of the DMA … to ensure that safe, efficacious, and high quality monoclonal antibody and related products are available to the American people to diagnose, prevent and treat the illnesses that afflict them. … to maintain and retain a diverse, knowledgeable, scientifically based and dedicated staff actively involved in research and regulatory review
  3. 3. Clinical Success of Monoclonal Antibodies “Monoclonal antibodies now comprise the majority of recombinant proteins currently in the clinic, with more than 150 products in studies sponsored by companies located worldwide.” Janice Reichert, Tufts University Center for the Study of Drug Development Nature Biotechnology, September 2005
  4. 4. The Division of Monoclonal Antibodies Kathleen Clouse, PhD. Director Patrick Swann, PhD. Deputy Director Regulatory Science & Policy Branch Patrick Swann, PhD, Chief Laboratory of Immunobiology Laboratory of Cell Biology Lab of Molec & Dev Immunol Marjorie Shapiro, PhD, Kathleen Clouse, PhD, Chief Marjorie Shapiro, PhD, Chief Acting Chief David Frucht, MD Counterbioterrorism: Anthrax
  5. 5. Dr. David Frucht • Established an independent research program to characterize the activity of anthrax lethal toxin in vitro and in vivo • Reviews products for infectious diseases, including antibodies under consideration for inclusion in the SNS under Emergency Use Authorization • Reviews monoclonal antibodies or related molecules that function as agonists or antagonists for hematologic indications • Participates in pre-approval inspections for MoAb products • Serves on working groups for guidance document development (anthrax therapeutics development, drug-drug interactions) • Co-Chair, CDER/CBER Inter-Center Biotechnology Counter- Terrorism Working Group • Chair, CMC session of the FDA-sponsored workshop on “Immune Therapies for Anthrax Infection”
  6. 6. Dr. David Frucht • Board certified in Internal Medicine & Infectious Diseases • Performs weekly clinical rounds at NIH • Serves on Editorial Boards for The Journal of Immunology and The Journal of Biological Chemistry • Awarded competitive HHS grants (2006 & 2007) and CBER/FDA grants (2002 & 2003) for CBT research efforts • Duties as a Commissioned Officer, U.S. Public Health Service - Incident Response Coordination Team, on-call every 5 months for deployment (six deployments in 3 years) - Selected for the Physicians’ Professional Advisory Committee to the Surgeon General
  7. 7. David Frucht, M.D. Research Program Objectives • Identify biological markers for the activity of anthrax lethal toxin (LT) in humans and animal models • Assess the biological significance of these markers in the pathology of toxemia and/or anthrax infection • Establish the scientific basis for development of more relevant bioassays to assess product potency *Important for addressing issues relevant to seeking approval for these products under the “Animal Rule” (i.e., efficacy testing in animal models and not in humans)
  8. 8. David Frucht, M.D. Research Program Milestones • Anthrax LT activates murine macrophages, leading to release of IL-1b and IL-18 (J Biol Chem, 2004) - Identification of new biomarkers & strain susceptibility factors • Anthrax LT targets human T cells, leading to a blockade in proliferation and cytokine production (J Immunol, 2005) - A pathogenic mechanism and basis for new bioassays • Anthrax LT blocks B cell proliferation and immunoglobulin production (J Immunol, 2006) - A pathogenic mechanism and basis for new bioassay
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×